September 15, 2022

ProMab Presents Nano-Cel – Ready-to-use mRNA-LNP at CAR-TCR Summit 2022!

  ProMab will be at the CAR-TCR Summit 2022 in Boston, MA! Please visit us at booth #C52 […]
March 10, 2022

Novel Bispecific CAR-T Cells Against Hematological Cancers

Dr. Vita Golubovskaya, Director of R&D at ProMab will be hosting a webinar with Agilent that incorporates some […]
June 2, 2021
bsAb webinar

ProMab Bispecific Antibody Webinar

Interested in learning more about Bispecific Antibody Engineering? ProMab will be hosting a webinar encompassing our Bispecific Antibody […]
October 21, 2020

ProMab CAR-T Webinar

ProMab Biotechnologies is the world’s first CRO committed to improving human health with a focus on immunotherapy, specifically […]
July 28, 2020
Quick Facts

ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial

ProMab’s humanized CD19 CAR-T platform is a CAR T-cell therapy approved for adults with treatment of relapsed and […]
February 25, 2020

Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA

  BERKELEY, Calif. & RICHMOND, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, […]
February 4, 2020

Products & Custom Orders for 2019 Novel Coronavirus Research

The 2019 novel coronavirus (2019-nCoV) is a new virus that causes respiratory illness in people and can spread […]
November 19, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

ProMab has recently had our work published in JoVE on the real-time cytotoxicity assay (RTCA) that we use […]
October 31, 2019

NantKwest Signs Worldwide License Agreement with ProMab

Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option […]
August 21, 2019

CAR-TCR Summit 2019

CAR-TCR Summit 2019 Come visit the ProMab team and learn about our new products & services Booth #50 […]